Stories about: CSL

The Australian stock market finished down today amid renewed concerns about the pace of the global economic recovery and as local investors await the outcome of tomorrow’s federal election, which has become too close to call.

CSL, Australia’s biggest biotech and the world’s second largest producer of plasma blood products, today reported an eight percent dip in full year net profit to $1.05 billion, as a rising Australian dollar dented overseas revenues.

The Australian stock market ended slightly up today as miners helped the bourse to resist to drag of poor performers such as Telstra, although it wasn’t enough to continue the run of five consecutive weekly gains.

The Australian stock market finished the week up for the fifth week in a row today as investor’s maintained their run of confidence despite weaker-than-expected jobs and retail sales data out of the US overnight.

The Australian stock market was down for the second day in a row today although it ended the month on a four-week winning streak.

The Australian stock market finished the week up today for the third week in a row, buoyed by a strong lead from Wall Street overnight which fuelled investor’s appetites for local banking and mining stocks.

RNA interference (RNAi) was little more than an enigmatic laboratory phenomenon just 15 years ago, but has since been fashioned into a Swiss Army knife, bristling with new blades and widgets for biological and medical research.

The Australian share market closed slightly down today after a lacklustre session in which investors kept to the sidelines following weak economic data out of the U.S overnight, while anticipation of a federal election being called in the next few days contributed to the subdued mood.

CSL announced today that it will invest $235 million over the next five years to develop a large scale biotechnology facility at its manufacturing site in Broadmeadows focussed on the late-stage development of new therapies for cancer, bleeding disorders, inflammation and infection.

PricewaterhouseCoopers has released its BioForum report for the fourth quarter FY10 showing a fall of 9.5 percent for the local Life Sciences Index, which performed slightly better than the broader market.